Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis B infection: pathogenesis and management.

A S Lok1

  • 1Division of Gastroenterology, University of Michigan and Ann Arbor VA Medical Center, 48109, USA. aslok@umich.edu

Journal of Hepatology
|March 23, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Duodenal Permeability Is Associated With Mucosal Microbiota in Compensated Cirrhosis.

Clinical and translational gastroenterology·2022
Same author

[Proper patient education improves hepatitis C patients' disease-related knowledge and antiviral treatment acceptance in rural China].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology·2019
Same author

Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.

Alimentary pharmacology & therapeutics·2018
Same author

The higher prevalence of truncal obesity and diabetes in American than Chinese patients with chronic hepatitis C might contribute to more rapid progression to advanced liver disease.

Alimentary pharmacology & therapeutics·2017
Same author

Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment.

Journal of viral hepatitis·2017
Same author

All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.

Alimentary pharmacology & therapeutics·2016

Hepatitis B virus (HBV) infection remains a significant global health concern. Future research focuses on developing effective, affordable therapies to inhibit HBV DNA and cccDNA, aiming for eradication despite social and economic challenges.

Area of Science:

  • Hepatology and Viral Immunology

Background:

  • Hepatitis B virus (HBV) infection, though ancient, has seen major advancements in understanding its epidemiology, pathogenesis, and treatment over the last 30 years.
  • Despite progress, 300 million people worldwide are HBV carriers, facing risks of liver failure and hepatocellular carcinoma.
  • Global eradication is technologically feasible but faces significant social and economic implementation hurdles.

Purpose of the Study:

  • To outline the future research directions for Hepatitis B, focusing on developing more effective therapies for chronic HBV infection.
  • To address the need for treatments that inhibit HBV DNA synthesis and eliminate cccDNA.
  • To explore challenges in HBV treatment and research, including occult infections, viral variants, and immune mechanisms.

Main Methods:

  • Review of current knowledge and projected advancements in Hepatitis B research.

Related Experiment Videos

  • Focus on developing novel antiviral and immunomodulatory therapeutic strategies.
  • Investigation into the prevalence of occult HBV infection and the significance of HBV variants.

    • Main Results:

    • Optimism for HBV eradication exists, but 300 million carriers remain at high risk.
    • New therapies are expected within 1-2 decades, likely involving combination treatments.
    • Challenges remain in providing affordable and accessible treatments globally.

    Conclusions:

    • Hepatitis B is not a past health problem; ongoing research is crucial for effective therapies.
    • Future treatments must be safe, convenient, affordable, and target both viral DNA and cccDNA.
    • Further research is needed on occult infections, HBV variants, and immune pathogenesis for comprehensive management.